3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
91
Carcinoma, Non-Small-Cell Lung
84
Neoplasms
48
Carcinoma, Renal Cell
44
Neoplasm Metastasis
40
Carcinoma, Hepatocellular
36
Squamous Cell Carcinoma of Head and Neck
35
Colorectal Neoplasms
31
Pancreatic Neoplasms
24
Lung Neoplasms
20
Stomach Neoplasms
19
Head and Neck Neoplasms
18
Carcinoma, Transitional Cell
17
Hodgkin Disease
16
Breast Neoplasms
16
Small Cell Lung Carcinoma
15
Ovarian Neoplasms
14
Urinary Bladder Neoplasms
13
Recurrence
13
Advanced Cancer
13
Glioblastoma
12
Brain Neoplasms
12
Lymphoma
11
Kidney Neoplasms
11
Glioma
11
Prostatic Neoplasms
10
Lymphoma, Non-Hodgkin
10
Uveal Melanoma
9
Triple Negative Breast Neoplasms
9
Sarcoma
9
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
Nivolumab
×
Clear all
NCT02973113
2021-07-21
PREVALE
Baylor College of Medicine
Phase 1
Completed
8 enrolled